Researchers used an 8-protein prognostic score termed the leukemia inflammatory risk score (LIRS) to identify inflammatory proteins with newly diagnosed AML.

Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline ...

Management of newly diagnosed acute myeloid leukemia (AML) in patients deemed unfit for intensive chemotherapy is undergoing ...

A fit and healthy University student passed away due to acute myeloid leukemia – a rare cancer, exactly a week after he was ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

The event will feature an overview of the ongoing Phase 3 REGAL trial of GPS (results expected by year-end) and a discussion of the unmet needs of AML patients in complete second remission (CR2).

Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...

The event will feature an overview of the ongoing Phase 3 REGAL trial of GPS (results expected by year-end) and a discussion of the unmet needs of AML patients in complete second remission (CR2).

Thanks to efforts from doctors, researchers, health care providers and nonprofits such as Blood Cancer United, certain types of blood cancers are not the terminal diagnoses that these were decades ago ...